TY - JOUR
T1 - Real-world experience using combination therapy with riociguat and risk assessment using REVEAL Lite 2.0 in patients with pulmonary arterial hypertension
AU - Sahay, Sandeep
AU - Rahaghi, Franck
N1 - © The Author(s) 2020.
PY - 2020/1
Y1 - 2020/1
N2 - Pulmonary arterial hypertension is a progressive disease that can lead to right-sided ventricular failure and premature death. Tailoring therapy to individual patient’s needs, along with regular risk assessment, is integral for optimal outcomes in patients with pulmonary arterial hypertension. Results from the AMBITION trial support the use of upfront combination of tadalafil and ambrisentan. In a recent analysis of risk assessment in pulmonary arterial hypertension, abridged versions of the REVEAL 2.0 risk score were shown to be comparable to the full tools. In this report, we present a case series of the use of riociguat in upfront combination or sequentially, and the impact on risk scores as determined by the abridged REVEAL Lite 2.0 approach.
AB - Pulmonary arterial hypertension is a progressive disease that can lead to right-sided ventricular failure and premature death. Tailoring therapy to individual patient’s needs, along with regular risk assessment, is integral for optimal outcomes in patients with pulmonary arterial hypertension. Results from the AMBITION trial support the use of upfront combination of tadalafil and ambrisentan. In a recent analysis of risk assessment in pulmonary arterial hypertension, abridged versions of the REVEAL 2.0 risk score were shown to be comparable to the full tools. In this report, we present a case series of the use of riociguat in upfront combination or sequentially, and the impact on risk scores as determined by the abridged REVEAL Lite 2.0 approach.
KW - chronic thromboembolic pulmonary hypertension
KW - pulmonary arterial hypertension
KW - pulmonary hypertension
KW - riociguat
UR - http://www.scopus.com/inward/record.url?scp=85081973286&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081973286&partnerID=8YFLogxK
U2 - 10.1177/2045894020910098
DO - 10.1177/2045894020910098
M3 - Article
AN - SCOPUS:85081973286
SN - 2045-8932
VL - 10
JO - Pulmonary Circulation
JF - Pulmonary Circulation
IS - 1
ER -